Supernus Pharmaceuticals
SUPN · Nasdaq · United States
Share price · SUPN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SUPN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026-32.8%
- 14 Oct 2026-4.4%
Nothing announced by SUPN that day or the session before.
- 5 Aug 2026+8.5%
- 4 Aug 2026-6.0%
- 9 Jul 2026-3.4%
Nothing announced by SUPN that day or the session before.
- 8 Jul 2026+5.2%
Nothing announced by SUPN that day or the session before.
- 11 May 2026-4.2%
Nothing announced by SUPN that day or the session before.
- 25 Feb 2026+5.7%
- 24 Feb 2026+5.1%
- 18 Feb 2026-2.8%
Nothing announced by SUPN that day or the session before.
Share of unusual movement by asset
For each asset, the share of SUPN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(10 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | NMDA receptorSmall molecule | Parkinson's Disease | |
| Approved | Dopamine receptor (non-ergoline agonist)Small molecule | Parkinson's Disease | |
| Approved | Dopamine receptor (non-ergoline agonist)Small molecule | Parkinson's Disease | |
| Approved | Voltage-gated sodium channelSmall molecule | Epilepsy Focal Onset Seizures | |
Safinamide(Xadago) | Approved | MAO-BSmall molecule | Parkinson's Disease |
| Approved | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseSmall molecule | EpilepsyMigraineLennox-Gastaut Syndrome Primary Generalized Tonic-Clonic Seizures | |
viloxazine(Qelbree) | Approved | norepinephrine transporterSmall molecule | Attention Deficit Hyperactivity Disorder |
| Phase 2 | AcetylcholinesteraseSmall molecule | EpilepsyDravet Syndrome | |
| Phase 2 | mTORC1Small molecule | Major Depressive Disorder | |
| Phase 2 | mTORC1 (mammalian target of rapamycin complex 1) (activator)Small molecule | Major Depressive Disorder |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $227M | $26M | $177M+ $184M short-term inv. | —$6.6M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $219M | $29M | $181M+ $192M short-term inv. | $58M-$4.8M operating cash flow | report ↗ |
| 2026-Q1 | $208M | $39M | $186M+ $199M short-term inv. | $2.3M$67M operating cash flow | report ↗ |
| 2025-Q3 | $192M | $29M | $153M+ $130M short-term inv. | $45M-$62M operating cash flow | report ↗ |
| 2025-Q2 | $165M | $22M | $145M+ $378M short-term inv. | —$59M operating cash flow | report ↗ |
| 2025-Q1 | $150M | $27M | $116M+ $348M short-term inv. | $12M$31M operating cash flow | report ↗ |
| 2024-Q4 | — | — | $319M+ $1.0M short-term inv. | —-$17M operating cash flow | report ↗ |
| 2024-Q3 | $176M | $29M | $32M+ $372M short-term inv. | —$54M operating cash flow | report ↗ |
| 2024-Q2 | $168M | $26M | $52M+ $295M short-term inv. | —$36M operating cash flow | report ↗ |
| 2024-Q1 | $144M | $25M | $63M+ $234M short-term inv. | —$38M operating cash flow | report ↗ |
| 2023-Q3 | $154M | $23M | $95M+ $105M short-term inv. | $16M$36M operating cash flow | report ↗ |
| 2023-Q2 | $136M | $24M | $25M+ $127M short-term inv. | $0.8M-$19M operating cash flow | report ↗ |
| 2023-Q1 | $154M | $21M | $462M+ $170M short-term inv. | —$49M operating cash flow | report ↗ |
| 2022-Q3 | $177M | $20M | $111M+ $280M short-term inv. | —$14M operating cash flow | report ↗ |
| 2022-Q2 | $170M | $16M | $173M+ $187M short-term inv. | —$71M operating cash flow | report ↗ |
| 2022-Q1 | $153M | $21M | $116M+ $196M short-term inv. | —$4.3M operating cash flow | report ↗ |
| 2021-Q3 | $148M | $20M | $215M+ $229M short-term inv. | —-$4.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $719M | $106M | $130M+ $180M short-term inv. | $9.6M$47M operating cash flow | report ↗ |
Supernus reported full-year 2025 revenue of $718.95M, up 8.6% YoY, with R&D spend of $106.24M, down 2.4% YoY. Cash, cash equivalents and current marketable securities were $308.7M at December 31, 2025, and the company reported a full-year net loss of $38.55M, with diluted loss per share of $0.68.
Management issued full-year 2026 guidance of $840M–$870M total revenues, $0–$30M operating earnings, and $140M–$170M adjusted operating earnings (non-GAAP). Clinically, the Phase 2b trial of SPN-817 for treatment-resistant focal seizures is ongoing, a follow-on Phase 2b trial of SPN-820 in major depressive disorder was initiated, and a Phase 1 study of SPN-443 is expected in the second half of 2026. Supernus also resumed new patient initiations for ONAPGO in the first quarter of 2026 after securing additional supply, following the product’s 2025 U.S. launch and the Sage Therapeutics acquisition.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $662M | $109M | $69M+ $384M short-term inv. | —$172M operating cash flow | report ↗ |
| 2023-FY | $608M | $92M | $75M+ $180M short-term inv. | —$111M operating cash flow | report ↗ |
| 2022-FY | $667M | $75M | $93M+ $368M short-term inv. | —$117M operating cash flow | report ↗ |
| 2021-FY | $580M | $90M | $203M+ $136M short-term inv. | —$127M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 20 sales ($10.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-02 | Sensenig Bethany · director | Other (see filing) (derivative) | 24,153 | — | — | Form 4 |
| 2026-11-02 | Hudson Frederick M. · director | Other (see filing) | 60,413 | — | — | Form 4 |
| 2026-11-02 | NEWHALL CHARLES W III · director | Other (see filing) | 124,119 | — | — | Form 4 |
| 2026-11-02 | Mottola Frank · SVP, Chief Tech. Ops. Officer | Other (see filing) | 19,544 | — | — | Form 4 |
| 2026-11-02 | Rubin Jonathan · SVP, Chief Medical Officer | Other (see filing) | 13,979 | — | — | Form 4 |
| 2026-11-02 | Bhatt Padmanabh P. · Sr. VP of IP, CSO | Other (see filing) | 18,637 | — | — | Form 4 |
| 2026-11-02 | Barlow Carrolee · director | Other (see filing) | 27,045 | — | — | Form 4 |
| 2026-11-02 | DEC TIMOTHY C · Senior Vice-President & CFO | Other (see filing) | 9,129 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 325 reporting institutions held 58.2M shares ($2.9B, 49.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 8,797,254 | $454.7M |
| 2 | MILLENNIUM MANAGEMENT LLC | 3,315,973 | $171.4M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3,238,693 | $167.4M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2,467,215 | $127.5M |
| 5 | DIMENSIONAL FUND ADVISORS LP | 2,307,030 | $119.2M |
| 6 | STATE STREET CORP | 2,288,127 | $118.3M |
| 7 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2,037,202 | $105.3M |
| 8 | ARMISTICE CAPITAL, LLC | 1,895,347 | $98.0M |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 1,705,222 | $88.1M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1,623,514 | $83.9M |
| 11 | CITADEL ADVISORS LLC | 1,493,446 | $77.2M |
| 12 | LOOMIS SAYLES & CO L P | 1,425,779 | $73.7M |
| 13 | Stephens Investment Management Group LLC | 1,351,331 | $69.9M |
| 14 | Point72 Asset Management, L.P. | 1,318,555 | $68.2M |
| 15 | Sofinnova Investments, Inc. | 954,309 | $49.3M |